Zencurix Acquires 'Nanobio Life'... "Strengthening Diagnostic Business"

Kim Soo-kyung, CEO of Nanobio Life (left), and Cho Sang-rae, CEO of GenCurix.

[Asia Economy Reporter Eunmo Koo] Zencurix announced on the 21st that it will acquire the in vitro diagnostic equipment specialist company ‘Nano Bio Life’. The acquisition amount is 5.7 billion KRW, and the post-acquisition shareholding ratio is 52.73%.

Through this acquisition, Zencurix aims to strengthen its in vitro diagnostic business and create synergy effects between the diagnostic reagent and diagnostic device businesses. Nano Bio Life develops precision diagnostic equipment, and Zencurix strengthens cooperation by developing and supplying related diagnostic kits.

Founded in 2015, Nano Bio Life is a company possessing high-sensitivity confocal optical detection technology and diagnostic reagent development technology. The point-of-care testing (POCT) device developed last year has the advantage of collecting signals at a finer dot level than the existing camera detection method’s surface method, resulting in higher detection sensitivity and accuracy.

In particular, due to the activation of non-face-to-face medical services following the COVID-19 pandemic, global demand for Nano Bio Life’s point-of-care diagnostic devices is increasing. Currently, Nano Bio Life’s equipment is used for diagnosing lung cancer multiplex diagnosis, cardiovascular diseases, ectopic pregnancy, and the demand for customized point-of-care diagnostic devices by disease is expected to continue growing.

Dr. Su-Kyung Kim, the founder of Nano Bio Life, is an expert who has specialized in researching and developing nano-optical technology for over 20 years at LG Electronics and the Electronics and Telecommunications Research Institute (ETRI). Dr. Kim succeeded in commercializing a rapid diagnostic kit point-of-care device with excellent performance by applying the world’s first optical pickup method microarray scanner technology.

A Zencurix official stated, “With the spread of various diseases and COVID-19, the importance of quantitative data analyzers that can resolve visual diagnostic errors is emerging,” and added, “We will target the market with Nano Bio Life’s excellent precision diagnostic equipment and Zencurix’s highly competitive diagnostic kits.”

He continued, “Nano Bio Life has also obtained sales approval from the Ministry of Food and Drug Safety and the European Conformity (CE) certification for its self-developed COVID-19 rapid diagnostic kit, thus possessing excellent diagnostic reagent development capabilities,” emphasizing, “We will maximize synergy in the diagnostic business by utilizing the technologies and networks held by both companies.”

This content was produced with the assistance of AI translation services.